Genomic medicine company Chroma Medicine Inc announced on Thursday the appointment of Melissa J Moore, PhD to its board of directors.
Dr Moore is currently a board director and Scientific Advisory Board member for multiple biotechnology companies. She previously served as chief scientific officer, Platform Research, at Moderna Inc (NASDAQ:MRNA).
Dr Moore co-founded the RNA Therapeutics Institute at the University of Massachusetts Medical School and was a professor of Biochemistry & Molecular Pharmacology, Eleanor Eustis Farrington Chair in Cancer Research, and a long-time Investigator at the Howard Hughes Medical Institute.
Catherine Stehman-Breen, M.D., Chroma CEO, said: "Melissa brings decades of experience directing RNA research and drug development at leading pharma companies and in academia. Her deep knowledge will benefit us as we advance our platform of highly potent and durable epigenetic editors to patients, enabling a new class of genomic medicines."
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
GSK announces submission of RSV vaccine Arexvy for FDA review
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
IGI and AbbVie enter global licensing agreement for ISB 2001
REGENXBIO reports RGX-202 preclinical results in Duchenne Muscular Dystrophy
MetaVia doses first patient in 48 mg MAD cohort of DA-1726 Phase 1 trial
GenScript Biotech awarded EcoVadis Silver Medal
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025